Ovarian cancer drug test promising | The Chronicle Herald
Monday, May 20, 2013 - 07:01
in Health & Medicine
A Halifax-based biotechnology company reported positive movement in its cancer vaccine programs in the first quarter. The first phase of Immunovaccine Inc.’s clinical study for its ovarian cancer vaccine, DPX-Survivac, showed positive results. “A Phase 2 trial is no …